PT-141 (Bremelanotide) vs Tadalafil
A side-by-side research comparison of PT-141 (Bremelanotide) and Tadalafil across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PT-141 (Bremelanotide) | Tadalafil |
|---|---|---|
| Full name | Bremelanotide (PT-141 / Vyleesi) | Tadalafil (Cialis) |
| Category | Sexual Health | Sexual Health |
| Status | FDA Approved | FDA-approved prescription |
| Mechanism | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. | Selectively inhibits phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in smooth muscle. This enhances nitric oxide signaling for vasodilation in penile, pulmonary, and prostate tissue. |
| Molecular weight | 1,025 Da | 389.40 Da |
| Half-life | 2.7 hours | ~17.5 hours |
| Bioavailability | High (SubQ) | ~36% oral |
| Typical dose | 1.75 mg | 2.5-5 mg daily or 10-20 mg as needed |
| Frequency | As needed, ~45 min before activity | Daily or on-demand |
| Route | Subcutaneous injection | Oral tablet |
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Tadalafil reported benefits
- Erectile function improvement
- Cardiovascular health (vasodilation)
- Prostate health (BPH)
- Improved exercise capacity
- Nitric oxide support
Related comparisons
Research and educational reference only. Not medical advice.